GHRP-2
Unapproved GHRP — not FDA-approved.
What it's for
GHRP-2 (pralmorelin) is a synthetic hexapeptide growth hormone release-nudge signal; pralmorelin has diagnostic use in some countries.
What it does for the body
Stimulates growth hormone release; researched and used diagnostically abroad. Not an FDA-approved chronic therapy in the U.S. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
Ghrelin receptors (lock-and-key landing spots on cells) activating its target pathway amplifies growth hormone pulses (also can affect appetite/cortisol to varying degrees). Imagine a thermostat for growth-hormone release: some peptides nudge the brain's release signals up, rather than pouring hormone in directly.
Research context
Bottom line for readers: GHRP-2 is best treated as a research-interest topic. Early papers can be fascinating; they are not a green light for self-experimentation.
Studied for (literature interest)
- Bones research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: GHRP-2 — FDA.gov search
- ClinicalTrials.gov search: GHRP-2 — U.S. clinical trials registry
- Drugs@FDA search: GHRP-2 — FDA drug database (if approved)
- PubMed search: GHRP-2 — NCBI PubMed
- PubMed Central search: GHRP-2 — NCBI PMC